An Oncology biotech pioneering  RAD51 inhibition to treat high replication stress tumors

Satya strengthens Scientific team

Srikant Viswanadha, an accomplished industry leader, has joined Satya as its CSO. Srikant has over 19 years’ pharmaceutical experience in reputed companies, and has been involved in the discovery and early clinical development of multiple programs. He was last the CSO at Incozen/ Rhizen.

Manoj Pothuganti has also joined Satya as a Program Lead and Associate Director, Biology. Manoj has had a stellar career at Aurigene, Glenmark and Intonation, prior to joining Satya
Scroll to Top